Perrigo would be good acquisition for Teva, says RBC Capital RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.
Sagent FY15 guidance could be 'well below' consensus, says Jefferies Jefferies says it sees several reasons why Sagent Pharmaceuticals' upcoming FY15 guidance could fall "well below" consensus estimates. The firm believes the launch of g-Venofer and g-Nembutal could be delayed until FY16, and it thinks Sagent's base business could see enhanced competition in FY15. Jefferies lowered its price target for shares to $27 from $33 and keeps a Hold rating on the name.